Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.36 |
| ▸ | ITGAV | P06756 | 12/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.32 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.32 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12158643 | 0.83 | ITGB3 (0.36) | ITGB3ITGAVUHRF1CXCR4ITGA2B | |
| SCHEMBL325029 | 0.83 | ITGB3 (0.39) | ITGB3ITGAVCXCR4ITGA2BNNMT | |
| SCHEMBL20091210 | 0.80 | UHRF1 (0.36) | ITGB3ITGAVUHRF1CXCR4ITGA2B | |
| SCHEMBL10258928 | 0.79 | NPC1 (0.39) | ITGB3ITGAVCXCR4ITGA2BNNMT | |
| SCHEMBL325441 | 0.79 | NPC1 (0.39) | ITGB3ITGAVCXCR4ITGA2BNNMT | |
| SCHEMBL325440 | 0.79 | NPC1 (0.39) | ITGB3ITGAVCXCR4ITGA2BNNMT | |
| SCHEMBL18105218 | 0.76 | ITGB3 (0.33) | ITGB3ITGAVUHRF1CXCR4ITGA2B | |
| SCHEMBL21329809 | 0.76 | ITGAV (0.36) | ITGB3ITGAVCXCR4ITGA2BITGB5 | |
| SCHEMBL1081853 | 0.76 | ITGAV (0.44) | ITGB3ITGAVCXCR4ITGA2BITGB5 | |
| SCHEMBL24194417 | 0.75 | ITGAV (0.35) | ITGB3ITGAVCXCR4ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-08-17 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-3929196-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM Corporation (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3050878-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | Fujifilm Corporation (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160199520-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| WO-2015046278-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | 富士フイルム株式会社 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ITGB3 2323/4885ITGAV 3525/4885UHRF1 3072/4885 |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | ITGAM, ITGAL, ITGB1 | ITGB3 8/4885ITGAV 9/4885UHRF1 4809/4885 |
| US-20160199520-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ITGB3 2366/4885ITGAV 3539/4885UHRF1 3068/4885 |
| US-20230257375-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | ITGA6, ITGA1, ITGA2 | ITGB3 9/4885ITGAV 11/4885UHRF1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.